GlassScriptPhysician profile
Sandler L Burkley
NPI 1700884525
$4,646.40
in general payments reported to CMS, 2019-2025
25 companies · $373 in 2025
The $373 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,147 · 2020: $163 · 2021: $1,013 · 2022: $576 · 2023: $722 · 2024: $653 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,747.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $703.24 | 2020-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $655.11 | 2019-2021 | |
| Coopervision INC. | $392.22 | 2019-2024 | Myday Contact Lens |
| Bausch & Lomb Americas INC. | $372.63 | 2023-2024 | Infuse, Miebo, Xiidra |
| Abbvie INC. | $342.80 | 2022-2024 | Lumigan, Durysta, Alphagan P |
| Allergan, INC. | $335.09 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $224.90 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $207.18 | 2020-2024 | Acuvue |
| Kala Pharmaceuticals, INC. | $204.97 | 2021 | |
| Optos, INC. | $204.87 | 2019-2020 | |
| Dompe US, INC. | $150.11 | 2022-2025 | Oxervate |
| Alcon Vision LLC | $146.71 | 2022-2025 | Tryptyr |
| Sight Sciences, INC. | $127.88 | 2021 | |
| Horizon Therapeutics Plc | $124.97 | 2021 | |
| Optovue, INC. | $90.34 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Staar Surgical Company | $67.86 | 2019 | |
| Aerie Pharmaceuticals, INC. | $58.34 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $58.12 | 2021-2023 | |
| Oyster Point Pharma, INC. | $43.49 | 2022-2025 | Tyrvaya |
| Johnson & Johnson Surgical Vision, INC. | $36.00 | 2019 | |
| Eyevance Pharmaceuticals LLC | $27.81 | 2022 | |
| Halozyme INC | $24.91 | 2021 | |
| Harrow Eye, LLC | $20.84 | 2024 | Vevye |
| Omeros Corporation | $13.60 | 2019 | |
| Abb Con-Cise Optical Group LLC | $12.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandler Burkley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.